GLP-1s and PCOS: what the early evidence shows for women with insulin resistance

The 30-second summary

• PCOS is a hormonal-metabolic condition affecting around 1 in 10 women of reproductive age, often involving insulin resistance.
• Small randomised trials of GLP-1s in women with PCOS show meaningful weight loss, modest improvements in androgen levels, and, in some studies, more regular cycles.
• GLP-1s are not approved for PCOS treatment. They are used in this population because of weight and metabolic effects. Fertility is a related, downstream consideration.

Why GLP-1s and PCOS overlap

PCOS is heterogeneous, but a large subgroup of women with PCOS share three features: elevated androgens (testosterone, DHEAS), irregular ovulation, and insulin resistance.

Insulin resistance matters here because the same hyperinsulinemia that drives weight gain also drives the ovaries to produce more androgens, which in turn disrupts ovulation. The cycle is mutually reinforcing.

GLP-1s break into this loop at two places. They reduce body weight, which reduces insulin resistance. And they directly improve insulin sensitivity through GLP-1 receptor signalling in the pancreas and liver. (Drucker DJ, Cell Metab 2018.)

The result is a plausible, mechanism-driven reason why GLP-1s might help women with PCOS, and why the early data, while small, is interesting.

What the small trials have shown

A handful of randomised and open-label studies, mostly in women with PCOS and obesity:

• Liraglutide vs metformin (Jensterle et al., 2019): Liraglutide 3 mg daily produced more weight loss (about 5.2 kg) than metformin in obese women with PCOS, and improved menstrual regularity more often. Eur J Endocrinol
• Semaglutide pilot trials (Carmina et al., 2023; multiple early-phase studies): Weight loss in the range expected from the STEP trials, modest reductions in free testosterone, and improvements in menstrual cyclicity in a subgroup. Endocrine Reviews
• Tirzepatide in PCOS: The first dedicated randomised trials are reading out in 2026 and 2027. Early data, including from SURMOUNT-1 subgroup analyses, suggests similar magnitudes of benefit.

The headline: weight loss is consistent, and weight loss is what fixes most of the PCOS metabolic picture. The drug-specific contribution beyond weight loss is harder to pin down, but the direction of effect is favourable.

What changes for women with PCOS on a GLP-1

A practical, observed pattern in women with PCOS who go on a GLP-1:

1. Cycles often become more regular: sometimes within three months, sometimes after a longer arc. For women with very irregular cycles, this can be the first signal that something is shifting before the scale shows it.
2. Hirsutism (excess body hair) and acne improve more slowly: usually 9 to 18 months. Hair follicles are slow to respond to changes in androgen exposure.
3. Fertility may improve. This is mostly indirect: weight loss restores ovulation in many women with PCOS. The implication: if you are not actively trying to conceive, your contraception plan needs to be reliable. (See our contraception article.)
4. Insulin resistance markers improve: fasting insulin, HOMA-IR, sometimes fasting glucose if it was elevated.

The benefits are not specific to GLP-1s. Most aggressive weight-loss interventions produce similar improvements in PCOS. The GLP-1 advantage is the magnitude and consistency of the weight loss.

What to think about before starting

A short list, for a woman with PCOS considering a GLP-1:

1. Confirm the diagnosis with an endocrinologist or your OB-GYN. PCOS is over-diagnosed and under-diagnosed in roughly equal measure. The Rotterdam criteria (irregular cycles, elevated androgens, polycystic ovaries on ultrasound, two of three required) remain the standard.
2. Get a baseline metabolic workup. Fasting glucose, HbA1c, fasting insulin, lipid panel, and androgens. These give you the line against which improvements will show up.
3. Plan for contraception. If you do not want to become pregnant, ovulation returning is a fertility risk on the same drug that is helping with weight.
4. Consider what the drug is doing vs what the weight loss is doing. If you stop the GLP-1, weight tends to come back. If weight comes back, PCOS markers come back. The maintenance plan matters.

What to talk to your prescriber about

• Have you seen weight loss alone produce these changes, or do you think the drug is doing something extra?
• What dose would we aim for, and how long?
• How will we monitor my androgens, cycles, and metabolic markers over the first year?
• If I want to conceive in 12–18 months, what is the plan to step off?

What this is not

This is not a recommendation to take a GLP-1 for PCOS. The drug is not approved for that indication. Prescribing it in PCOS is off-label, common, and increasingly evidence-based, but the data is still building.

It is also not a substitute for the other parts of PCOS care: diet, exercise, sometimes metformin, sometimes hormonal therapy. A GLP-1 is a tool that fits into a broader plan, not the entire plan.

What Steady does with this

Steady tracks cycle phase, weight, and symptoms in the same place. For a woman with PCOS, the symptom log (acne, hirsutism, mood, energy) and the cycle log (period start, length, regularity) tend to move in opposite directions over the first six months, the symptoms improve as cycles regularise. Seeing both lines on the same chart, alongside weight, makes the picture coherent in a way most apps cannot.

Sources

1. Drucker DJ. Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metab 2018. Cell Metab
2. Jensterle M et al. Liraglutide vs metformin in obese PCOS. Eur J Endocrinol 2019. EJE
3. Carmina E, Rosato F. GLP-1 agonists in PCOS, review. Endocr Rev 2024. Endocrine Reviews
4. International evidence-based PCOS guideline 2023. Monash University

Medical disclaimer: Off-label prescribing in PCOS is a conversation with an endocrinologist or OB-GYN, not the internet. See our full medical disclaimer.